GLPwatch
Papers (10409)
Page 124 of 174, ranked by citation count.
- Tirzepatide: NICE recommends another GLP-1 agonist for type 2 diabetes.
- Bringing liraglutide to market: a CER case study.
- Hydrophobic Tag-Assisted Liquid-Phase Synthesis of Tirzepatide.
- Weight Loss That Lasts: Reviewing the Long-Term Impact of GLP-1 Receptor Agonists.
- Pancreas and liver uptake of new radiolabeled incretins (GLP-1 and Exendin-4) in models of diet-induced and diet-restricted obesity.
- Carbol fuchsin stain enhances detection of poly-(d, l-lactide-co-glycolide) microspheres in exenatide extended-release cutaneous injection-site foreign body reaction.
- Maturity-Onset Diabetes of the Young (MODY) With HNF1B p.Glu105Lys Mutation Achieving Significant Insulin Reduction on Tirzepatide: A Case Report.
- Liraglutide Treatment Does Not Induce Changes in the Peripapillary Retinal Nerve Fiber Layer Thickness in Patients with Diabetic Retinopathy.
- Clinical pearls for initiating and utilizing liraglutide in patients with type 2 diabetes.
- Glp-1 Receptor Agonists Regulate the Progression of Diabetes Mellitus Complicated with Fatty Liver by Down-regulating the Expression of Genes Related to Lipid Metabolism.
- Comparative Analysis of the Anti-Inflammatory Effects of Liraglutide and Dulaglutide.
- Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development.
- Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes.
- Cutaneous Adverse Events Associated With GLP-1 Receptor Agonists: A FAERS Database Analysis From 2018-2024.
- Effectiveness and safety of daily oral semaglutide in people with type 2 diabetes mellitus switching from sulfonylureas: A real-world retrospective study.
- [A new era for glucagon-like peptide-1 receptor agonists].
- Modeling the impact of preplanned dose titration on delayed response.
- Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26-week open-label feasibility study.
- Liraglutide's Effect on Weight Management in Subjects With Pre-diabetes: A Systematic Review & Meta-Analysis.
- Epicardial adipose tissue and residual cardiovascular risk: a comprehensive case analysis and therapeutic insights with Liraglutide.
- Semaglutide-Associated Gastric Pneumatosis.
- The Integration of Lifestyle Modification Advice and Diet and Physical Exercise Interventions: Cornerstones in the Management of Obesity with Incretin Mimetics.
- Liraglutide modulates morpho-functional and inflammatory gastrointestinal responses in rats.
- Allodynia and Dysesthesia Associated With Semaglutide and Tirzepatide.
- Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice.
- Effectiveness of the Dual GIP/GLP1-Agonist Tirzepatide in 2 Cases of Alström Syndrome, a Rare Obesity Syndrome.
- Liraglutide and Weight Loss Among Suboptimal Responders to Metabolic Bariatric Surgery: A Randomized Clinical Trial.
- Revolutionizing diabetes care: unveiling tirzepatide's potential in glycemic control and beyond.
- Anti-Diabetic Agents and Heart Failure - Response to the CARMELINA Study.
- Efficacy and safety of fixed-ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials.
- Supramolecular prodrug of SN38 based on endogenous albumin and SN38 prodrug modified with semaglutide side chain to improve the tumor distribution.
- GLP-1 Signalling as a Therapeutic Avenue in Parkinson's Disease: A Comprehensive Review.
- Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy.
- Investigating the potential non-authorized use of two different formulations of liraglutide in Europe: A real-world drug utilization study.
- Effects of Combination Treatment with Leptin and Liraglutide on Glucose Metabolism in Insulin-Dependent Diabetic Mice.
- Impact of degradation in subcutaneous tissue and lymphatic fluid on absorption of Fc-fusion proteins following subcutaneous administration.
- Strategies to Enhance the Therapeutic Efficacy of GLP-1 Receptor Agonists through Structural Modification and Carrier Delivery.
- Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity.
- Obesity as a Chronic Disease: A Narrative Review of Evolving Definitions, Management Strategies, and Cardiometabolic Prioritization.
- Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study.
- Variation in the Commissioning of Semaglutide for the Treatment of Obesity and Overweight Across England: Results of Three Freedom of Information-Based Mapping Exercises Across the 42 Integrated Care Boards of England.
- In the Eye of Controversy: A Deeper Look Into the Impact of Glucagon-like Peptide-1 Receptor Agonists on Diabetic Retinopathy and Nonarteritic Anterior Ischemic Optic Neuropathy.
- How to 'drug' our way out of the obesity crisis (or not): the roll-out of semaglutide.
- Drug-Induced Liver Injury Due to Dulaglutide Use.
- Liraglutide for Adolescents with Obesity. Reply.
- [LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE TREATMENT OF OBESITY].
- Weight Loss in Veterans with Schizophrenia and Multimorbidity Prescribed Semaglutide: Results From a National Retrospective Cohort Study.
- Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
- US Population Eligibility and Estimated Impact of Tirzepatide Treatment on Obesity Prevalence and Cardiovascular Disease Events.
- Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.
- Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease.
- Unlocking the potential of glucagon-like peptide-1 receptor agonists in revolutionizing type 2 diabetes management: a comprehensive review.
- Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson's disease.
- Efficacy and safety of once-weekly tirzepatide in Japanese participants with type 2 diabetes who have obesity or overweight: Subpopulation analysis of the SURMOUNT-2 trial.
- Efficacy of tirzepatide for weight loss and it's comparative effectiveness to weight loss surgery in inflammatory bowel disease.
- Downstream interaction by glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonism is required for synergistic effects on body weight.
- Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study.
- Place in therapy for liraglutide and saxagliptin for type 2 diabetes.
- Time to approve glucagon-like peptide-1 receptor agonists for MASLD: a rational step based on robust evidence.
- A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.